Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Inventors

Han, Sangdon • Kim, Sun Hee • ZHU, Yunfei

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12492181-B2

Patent

Publication Date

2025-12-09

Expiration Date


Abstract

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Core Innovation

The disclosure describes gem-disubstituted piperidine compounds of Formula (I), including compounds of Formulae (IIa) and (IIb), or pharmaceutically acceptable salts thereof, as melanocortin receptor modulators and selective MC2R antagonists. Structural embodiments encompass Formulae Vd–Vp, VI/VIa–VId, VIIa–VIIf, VIII, IX/IXa, and X/Xa–Xc with variable aryl and heteroaryl groups, ring nitrogens, linker orientations, and amide, carbamate, or urea linkages. These disclosed entities encompass bipyridyl, arylpyridyl, pyrrolylpyridyl, and pyridazinyl analogues, as well as associated stereoisomers, active metabolites, and prodrug forms.

The claims cover a structural genus of Formula (IIa) or Formula (IIb) and an enumerated set of specific compounds, principally piperidine-4-carboxamides and related amide, carbamate, and urea structures. The provided descriptions further encompass pharmaceutically acceptable salts, solvates, stereoisomers, and amine-containing substituents. Reported hMC2R binding screening results indicate potent activity for tested compounds across the series, whereas the specific problem being solved is not explicitly described in patent.

Claims Coverage

The provided claims identify two independent claims representing two inventive features: a compound genus defined by Formula (IIa) or Formula (IIb), and an enumerated set of specific piperidine-based compounds.

Compounds of formula (IIa) or formula (IIb)

Independent claim 1 covers a compound of Formula (IIa) or Formula (IIb), or a pharmaceutically acceptable salt thereof, wherein RA and RB are unsubstituted or substituted phenyl or heteroaryl groups, X1–X4 are CR11–CR14 or N, and substituents including R1 are selected from defined alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, and nitrogen-containing groups.

Enumerated piperidine-based compounds

Independent claim 16 covers an enumerated set of specific piperidine-based compounds, principally piperidine-4-carboxamides, as well as related amide, carbamate, and urea structures, or a pharmaceutically acceptable salt thereof, with varied aromatic groups, nitrogen-containing substituents, and stereochemistry.

The independent claims cover both a broadly defined compound genus of Formula (IIa) or Formula (IIb) and a specified list of enumerated piperidine compounds, including pharmaceutically acceptable salts thereof, with dependent claims providing pharmaceutical compositions and therapeutic uses.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Administration of a claimed compound or a pharmaceutically acceptable salt thereof to treat Cushing's syndrome, ectopic Cushing's syndrome, ectopic ACTH syndrome, or congenital adrenal hyperplasia, or to reduce ACTH secretion or ACTH-driven effects in a mammal.

Pharmaceutical compositions comprising a claimed compound, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, including parenteral, oral, and topical formulations such as a topical gel.

Therapeutic regimens for conditions benefiting from melanocortin-receptor modulation.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.